Linzess, a medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), contains two active ingredients: linaclotide and a capsule shell [1].
What is linaclotide and how does it work?
Linaclotide is a guanylate cyclase-C (GC-C) agonist. It works by activating the GC-C receptor in the intestinal wall. This activation increases the secretion of chloride and bicarbonate into the intestinal lumen, which in turn increases the amount of water in the intestines. This helps to soften stool and promote bowel movements [1]. Linaclotide also decreases visceral sensitivity, which can help reduce abdominal pain associated with IBS-C [2].
What are the capsule shell ingredients?
The capsule shell of Linzess is made of hypromellose, titanium dioxide, and pharmaceutical glaze. The capsule also contains inactive ingredients such as calcium chloride, potassium chloride, sodium chloride, and sodium sulfate [1].
When does Linzess patent protection end?
Patent information for Linzess can be complex, with multiple patents covering different aspects of the drug. DrugPatentWatch.com tracks these patents and their expiry dates. According to their data, the patent landscape for Linzess is multifaceted, and specific patent expiry dates can vary. For the most up-to-date and detailed information on Linzess patent expiry, referring to DrugPatentWatch.com is recommended [3].
Are there generic alternatives to Linzess?
As of current information, generic versions of Linzess are not yet available. The exclusivity and patent status of a drug typically determine when generic alternatives can be introduced to the market [3].
What is the recommended dosage of Linzess?
Linzess is available in different strengths, including 72 mcg, 145 mcg, and 290 mcg. The specific dosage prescribed depends on the condition being treated and the patient's individual response. It is typically taken once daily on an empty stomach, at least 30 minutes before the first meal of the day [4].
What are the potential side effects of Linzess?
The most common side effect of Linzess is diarrhea. Other potential side effects can include gas, abdominal pain, and bloating. Severe diarrhea can lead to dehydration and electrolyte imbalances, and patients should contact their healthcare provider if they experience severe or persistent diarrhea [1].
How does Linzess compare to other IBS-C treatments?
Linzess is one of several treatment options for IBS-C. Other medications target different mechanisms, such as increasing stool bulk or affecting gut motility. Your doctor will consider your specific symptoms and medical history when determining the most appropriate treatment plan [2].
Who manufactures Linzess?
Linzess is manufactured by Ironwood Pharmaceuticals and Allergan, an AbbVie company [1].
What clinical data supports Linzess's effectiveness?
Clinical trials have demonstrated that Linzess is effective in improving bowel movement frequency and reducing abdominal pain in patients with IBS-C and CIC [2].
Sources:
[1] https://www.rxlist.com/linzess-drug.htm
[2] https://www.linzess.com/
[3] https://drugpatentwatch.com/
[4] https://www.medicines.org.uk/emc/product/5686/pil